News
LMAT
63.26
+1.02%
0.64
Here's Why You Should Retain Medtronic (MDT) Stock for Now
NASDAQ · 2d ago
Weekly Report: what happened at LMAT last week (0408-0412)?
Weekly Report · 5d ago
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
NASDAQ · 04/12 15:04
Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio
NASDAQ · 04/12 15:00
Here's Why You Should Add DaVita (DVA) to Your Portfolio
NASDAQ · 04/10 17:35
Why You Should Add Ensign Group (ENSG) to Your Portfolio Now
NASDAQ · 04/08 17:56
Glaukos (GKOS) Hits 52-Week High: What's Driving the Stock?
NASDAQ · 04/08 14:41
BD's (BDX) Latest Product to Offer Wider Access to Researchers
NASDAQ · 04/08 14:27
Weekly Report: what happened at LMAT last week (0401-0405)?
Weekly Report · 04/08 11:32
Weekly Report: what happened at LMAT last week (0325-0329)?
Weekly Report · 04/01 11:29
Here's Why Investors Should Hold Teladoc (TDOC) Stock Now
NASDAQ · 03/28 15:44
LeMaitre to Present at the 23rd Annual Needham Virtual Healthcare Conference
Barchart · 03/26 15:52
Weekly Report: what happened at LMAT last week (0318-0322)?
Weekly Report · 03/25 11:33
Compelling Reasons to Hold on to UnitedHealth Group (UNH) Stock
NASDAQ · 03/22 17:02
Weekly Report: what happened at LMAT last week (0311-0315)?
Weekly Report · 03/18 11:30
Markets Performance Review - February Dividend Income Report
The Dividend Guy does a market review of both the U.S. And Canadian stock market’s performance. Khanchit Khirisutchalual has invested 100% of his pension money in dividend growth stocks since September of 2017. His portfolio has returned 129.69% since inception in March 2024. He says the market is overvalued.
Seeking Alpha · 03/15 16:50
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
NASDAQ · 03/15 16:46
Best Momentum Stocks to Buy for March 13th
NASDAQ · 03/13 14:00
New Strong Buy Stocks for March 13th
NASDAQ · 03/13 12:10
Ex-Dividend Reminder: MDU Resources Group, LeMaitre Vascular and Valley National Bancorp
NASDAQ · 03/11 14:17
More
Webull provides a variety of real-time LMAT stock news. You can receive the latest news about Lemaitre Vasculr through multiple platforms. This information may help you make smarter investment decisions.
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.